Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epalorlimovalizumab + bevacizumab + TAS-102 vs bevacizumab + TAS-102 in advanced colorectal cancer
ChiCTR2500106797Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iparomlimab + tuvonralimab in colorectal adenocarcinoma (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Mar 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500106797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106797.